TLSI vs OTLY Comparison

TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.

Oatly Group AB produces and distributes oat-based food and beverage products. Its offerings include milk, cooking creams, spreads, and yogurts. The company's products are sold through retail stores, coffee shops, and restaurants across multiple countries. It generates revenue from sales of oatmilk and other oat-based products. The company's geographical segments include Europe & International, North America and Greater China. The Europe & International segment is its maximum revenue-producing segment, followed by the North America and Greater China segments.